Greenwave Technology Solutions, Inc. (GWAV): Entry into a Material Definitive Agreement

Greenwave Technology Solutions said Nasdaq issued an additional delinquency notice on May 21, 2026 for its delayed Q1 2026 Form 10-Q filing, citing noncompliance with Nasdaq Listing Rule 5250(c)(1). The company previously received a delinquency notice for its late 2025 Form 10-K. Nasdaq gives until June 22, 2026 to submit a compliance plan; trading remains on Nasdaq under “GWAV.”

Altria (MO) raised its quarterly dividend by 4.7% to $1.11/share, yielding ~6.4% at $68.37. The company has a strong free cash flow history but faces revenue decline and high debt. It guided for mid-single-digit dividend growth through 2028 and has a new contract manufacturing deal with Philip Morris International.

Walmart settled a U.S. government lawsuit accusing it of contributing to the opioid epidemic by unlawfully dispensing prescriptions. The Justice Department sued in 2020, potentially seeking billions in penalties. Walmart previously settled similar lawsuits for $3.1 billion in 2022. Terms of the latest settlement were not disclosed.

NuScale Power (SMR +5.07%) has a market cap near $4B, driven by a potential deal with TVA for 72 of its 77-MW reactors. However, NuScale is not a party to the agreement, which was signed between TVA and ENTRA1 Energy, its commercialization partner. NuScale would supply the reactor technology but not own or operate the plants. The deal is non-binding, and NuScale has paid $507.4M in milestone payments to ENTRA1, with larger payments pending. NuScale's Q2 2026 revenue was $75K, and it has no net i

Kazia Therapeutics (KZIA) shares fell 6.2% premarket after pricing a $40M public offering at $15.50 per ADS. The company will sell 2.58M ADSs and offer warrants for additional proceeds. Proceeds will fund clinical development of paxalisib and general corporate purposes. The offering is expected to close by August 31, 2026.

Novavax (NVAX) partners Sanofi and Takeda received approvals for the Nuvaxovid™ vaccine targeting the SARS-CoV-2 XFG variant for the 2026-2027 season in the U.S., EU, and Japan. Novavax will earn royalties on sales without commercial infrastructure, continuing its partnership strategy. Sanofi expands U.S. marketing and launches in new markets, while Takeda's Nuvaxovid became the second-leading COVID-19 vaccine in Japan.